Concurrent Proton-Pump Inhibitors Increase Risk of Death for Lung Cancer Patients Receiving 1St-Line Gefitinib Treatment - a Nationwide Population-Based Study
Total Page:16
File Type:pdf, Size:1020Kb
Cancer Management and Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study This article was published in the following Dove Press journal: Cancer Management and Research Yu-Hung Fang 1 Purpose: Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentra- – Yao-Hsu Yang 2 5 tion of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, Meng-Jer Hsieh 6,7 the adverse effect of PPIs on patients with non-small cell lung cancer (NSCLC) treated with Ming-Szu Hung8,9 first-line EGFR TKIs remains controversial. This study was conducted to evaluate whether Yu-Ching Lin 1,8 the combined use of gefitinib with PPIs affected NSCLC outcomes. 1Division of Thoracic Oncology, Department of Patients and methods: We performed a nationwide cohort study of patients newly Pulmonary and Critical Care Medicine, Chang diagnosed with NSCLC between 1997 and 2013 using the Taiwan Cancer Registry and Gung Memorial Hospital, Chiayi Branch, Puzi For personal use only. fi City, Chiayi County, Taiwan, R.O.C; Taiwan National Health Insurance databases. We identi ed patients who were treated with 2Department of Traditional Chinese Medicine, first-line EGFR TKIs and analyzed the association between use of PPIs and TKI treatment Chang Gung Memorial Hospital, Chiayi Branch, fi Puzi City, Chiayi County, Taiwan, R.O.C; outcome. We de ned the coverage ratio of PPIs as duration of PPI treatment in days divided 3Center of Excellence for Chang Gung by duration of TKIs in days. Patients who exhibited an overlap of >20% between PPI and Research Datalink, Chang Gung Memorial fi Hospital, Chiayi Branch, Puzi City, Chiayi TKI usage days were de ned as having a high coverage ratio. County, Taiwan, R.O.C; 4Institute of Results: A total of 1278 patients were treated with first-line gefitinib, 309 of which took Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public PPIs at the same time and 145 had a high PPI coverage ratio. Patients had similar time to 5 Health, Taipei City, Taiwan, R.O.C; School of failure regardless of their PPI coverage ratio during gefitinib treatment. However, higher PPI Traditional Chinese Medicine, College of Medicine, Chang Gung University, Guishan coverage ratio significantly decreased overall survival (OS) compared with that of patients Township, Taoyuan County, Taiwan, R.O.C; with a lower PPI coverage ratio or no PPI treatment in univariate analysis (median OS, 13.5, 6Department of Respiratory Therapy, College of Medicine, Chang Gung University, Guishan 16.7, and 21.8 months, respectively, p<0.01) and multivariate analyses (high coverage ratio Township, Taoyuan County, Taiwan, R.O.C; HR: 1.67; low coverage ratio HR: 1.29). Exposure to PPIs during first line gefitinib treatment 7Division of Pulmonary Infection and Critical Cancer Management and Research downloaded from https://www.dovepress.com/ by 54.70.40.11 on 21-Oct-2019 Care Medicine, Department of Pulmonary and significantly decreased overall survival of patients with NSCLC. Critical Care Medicine, Chang Gung Memorial Concurrent use of PPIs was associated with lower overall survival in patients Hospital, Chiayi Branch, Puzi City, Chiayi Conclusion: County, Taiwan, R.O.C; 8Department of with EGFR-mutant NSCLC under first-line gefitinib treatment. Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Puzi Keywords: proton pump inhibitor, epidermal growth factor receptor, non-small cell lung City, Chiayi County, Taiwan, R.O.C; 9School of cancer, gefitinib, tyrosine kinase inhibitor, National Health Insurance Research Database Medicine, College of Medicine, Chang Gung University, Guishan Township, Taoyuan County, Taiwan, R.O.C Introduction 1 Correspondence: Yu-Ching Lin Lung cancer is the leading cause of cancer-related mortality worldwide. Over the Division of Thoracic Oncology, last decade, one of the most important advances for the therapy of non-small cell lung Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial cancer (NSCLC) was the development of epidermal growth factor receptor (EGFR) Hospital, Chiayi Branch, No.6, W. Sec., tyrosine kinase inhibitors (TKIs).2,3 EGFR mutations are detected in more than 50% Jiapu Road, Puzi City, Chiayi County 4,5 61363, Taiwan, R.O.C of patients with the histological subtype of adenocarcinoma in East Asia. Among Tel +886 5 362 1000 Ext 2762 patients harboring an activating EGFR mutation, EGFR-TKIs significantly improve Fax +886 5 362 3005 6 7–9 Email [email protected] not only the patient’s quality of life, but also progression-free survival (PFS) and submit your manuscript | www.dovepress.com Cancer Management and Research 2019:11 8539–8546 8539 DovePress © 2019 Fang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work http://doi.org/10.2147/CMAR.S222278 you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Fang et al Dovepress overall survival (OS)10 compared with platinum-based the Bureau of NHI. The institutional review board of doublet chemotherapy. Nevertheless, almost all patients Chang Gung Memorial Hospital proved that patient con- who initially respond to EGFR-TKIs eventually show dis- sent was not required to review their medical records in ease progression. Many studies have aimed to extend the this retrospective database study (201700257B1). Patients’ effective period of EGFR-TKIs.11 However, identifying anonymity and confidentiality were ensured throughout the potential drug-drug interactions that may reduce the effi- study. cacy of EGFR-TKIs is equally important. There are two widely available first-generation EGFR- Definition of lung cancer TKIs, gefitinib and erlotinib, and most studies have focused Using the NHIRD, we identified patients older than 18 years on erlotinib.12 The recommended dose of gefitinib (250 mg/ of age with lung cancer according to the 9th Revision day) for NSCLC is around only one-third of its maximum International Classification of Disease, Clinical Modification tolerated dose, but the recommended dose used for erlotinib [ICD-9-CM] code 162 from the Registry of Catastrophic (150 mg/day) is its maximum tolerated dose.13 Besides, Illness Patients Database. The Registry of Catastrophic compared with gefitinib, exposure to erlotinib results in Illness Patients Database is a subset of NHIRD, and patholo- both higher maximum plasma concentration (Cmax) and gical confirmation of lung cancer is required to apply this the area under the serum concentration versus time curve registry. (AUC) at standard dosing.14 Therefore, we assume that the effects of gefitinib are more likely to be affected by con- Definition of first-line EGFR-TKI current drug treatments than the effects of erlotinib would. Among patients with ICD-9-CM code 162 between 1997 Proton pump inhibitors (PPIs), the major treatment for and 2013, we used Anatomical Therapeutic Chemical patients with reflux esophagitis or peptic ulcers, are one of (ATC) code to identify patients with NSCLC who were the most widely used classes of drugs in the world. In treated with gefitinib between Jun 2011 and Jun 2013. This timeline was chosen because NHI has reimbursed EGFR- For personal use only. healthy volunteers, PPI use may decrease the AUC and peak plasma concentration of first-generation EGFR- TKIs as a first-line therapy for late-stage EGFR-mutant TKIs.15 However, the clinical impact of PPIs on the treat- primary lung cancer since Jun 2011. ment outcome of EGFR-TKIs remains controversial.12,16–18 According to the NHI policy, physicians must seek There have been few large, multi-center studies focused on approval every 3 months when prescribing first-line patients receiving first-line EGFR-TKIs, and all the studies EGFR-TKIs with initial pathological diagnosis, EGFR fi enrolled patients being treated with other antacid agents, not mutation type analysis, and image evidence con rming PPIs only. Therefore, we used nationwide data from the advanced lung cancer in patients, and re-apply every Taiwan National Health Insurance Research Database to 3 months according to the tumor response as evaluated evaluate the impact of PPIs on first-line EGFR-TKIs treat- by image studies with chest computer tomography, bone ment outcomes. scans, and brain magnetic resonance imaging, which must be peer reviewed. NHI policy states that EGFR-TKI use is Cancer Management and Research downloaded from https://www.dovepress.com/ by 54.70.40.11 on 21-Oct-2019 not allowed beyond radiological progression. Materials and methods To exclude patients who were not taking first-line Data source EGFR-TKIs, we identified patients who had received In Taiwan, the National Health Insurance (NHI) is a sin- prior chemotherapy using ATC codes including: gle-payer mandatory national health insurance system that L01XA01 (Cisplatin); L01XA02 (Carboplatin); L01BA04 covers more than 99% of citizens and provides compre- (Pemetrexed); L01CA04 (Vinorelbine); L01CD01 (Paclit- hensive medical care.19 The National Health Insurance axel); L01CD02 (Docetaxel); and L01BC05 (Gemcit- Research Database (NHIRD), established by the National abine). Health Research Institutes (NHRI) of the Taiwanese gov- Thus, according to the NHI policy, patients taking first- ernment, is one of the largest and most complete health- line EGFR-TKIs without previous chemotherapy must care databases in the world, and has been used to have late-stage EGFR-mutant primary lung cancer.